Market Alert: Gold and Silver Extend Bull Run Amid Global Uncertainty
INOVIQ Limited (ASX: IIQ) has successfully completed an AU$9.5 million placement to institutional and sophisticated investors at AU$0.35 per share, alongside a AU$2 million Share Purchase Plan (SPP). Hong Kong–listed Tian An Medicare Limited (HKG:0383) contributed AU$5 million as cornerstone investor, supporting INOVIQ’s mission to advance its EXO-OC™ ovarian cancer test and exosome-based therapeutic platform for solid tumours.
Proceeds will fund clinical validation, commercial readiness, and preclinical studies while strengthening INOVIQ’s cash position to approximately AU$17.2 million post-raise. CEO Dr Leearne Hinch said the investment will “accelerate delivery of key value milestones” and expand global partnerships, particularly in China. With its cutting-edge exosome technology and 100% sensitivity in early-stage detection, INOVIQ is driving innovation in women’s health diagnostics and oncology therapeutics.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Oct 13, 2025
Oct 13, 2025
Oct 13, 2025
Oct 13, 2025
Oct 13, 2025
Oct 13, 2025
Oct 13, 2025
Oct 13, 2025
Oct 13, 2025
Oct 10, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
